Last reviewed · How we verify
Isatuximab Carfilzomib Lenalidomide Dexamethasone
This is a four-drug combination regimen that targets multiple pathways in multiple myeloma: isatuximab blocks CD38 on myeloma cells, carfilzomib inhibits the proteasome, lenalidomide is an immunomodulatory agent, and dexamethasone is a corticosteroid.
This is a four-drug combination regimen that targets multiple pathways in multiple myeloma: isatuximab blocks CD38 on myeloma cells, carfilzomib inhibits the proteasome, lenalidomide is an immunomodulatory agent, and dexamethasone is a corticosteroid. Used for Multiple myeloma (relapsed/refractory or newly diagnosed).
At a glance
| Generic name | Isatuximab Carfilzomib Lenalidomide Dexamethasone |
|---|---|
| Also known as | Isa-KRD |
| Sponsor | European Myeloma Network B.V. |
| Drug class | Combination therapy: monoclonal antibody + proteasome inhibitor + immunomodulatory agent + corticosteroid |
| Target | CD38 (isatuximab); proteasome (carfilzomib); cereblon (lenalidomide); glucocorticoid receptor (dexamethasone) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Isatuximab is a monoclonal antibody against CD38 that promotes myeloma cell death through antibody-dependent cellular cytotoxicity and direct apoptosis. Carfilzomib is a proteasome inhibitor that causes accumulation of toxic proteins in myeloma cells. Lenalidomide enhances immune responses against myeloma and has direct anti-proliferative effects. Dexamethasone provides additional anti-myeloma activity and reduces inflammation.
Approved indications
- Multiple myeloma (relapsed/refractory or newly diagnosed)
Common side effects
- Thrombocytopenia
- Anemia
- Neutropenia
- Peripheral neuropathy
- Fatigue
- Diarrhea
- Infections
- Cardiac toxicity
Key clinical trials
- KRDI in Transplant-Eligible MM (PHASE2)
- Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (PHASE3)
- Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) (PHASE3)
- International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab (PHASE2)
- MInimal Residual Disease Adapted Strategy (PHASE3)
- Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: